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Manipulation of the MHC-I presentation pathway, and thus limiting MHC-I cell surface
expression, is used by many viruses to evade immune recognition. In particular,
downregulation of MHC-I molecules at the cell surface can reduce the ability of CD8+
T cells to recognize viral peptides presented by MHC-I molecules and thereby delay
viral clearance by CD8+ T cells. To date, MHC-I downregulation by influenza viruses
has not been reported. Given that influenza virus infections are a global health concern
and that CD8+ T cells play an important role in promoting influenza virus clearance
and recovery from influenza disease, we investigated whether influenza A and B viruses
(IAV, IBV) downregulated MHC-I as a novel mechanism to evade cellular immunity.
Here, we showed that infection of several cell types, including epithelial A549 cells,
with a panel of IAV and IBV viruses downregulated the surface MHC-I expression
on IAV/IBV-infected cells during the late stages of influenza virus infection in vitro.
This observation was consistent across a panel of class I-reduced (C1R) cell lines
expressing 14 different HLA-A or -B alleles and a panel of 721.221 cell lines expressing
11 HLA-C alleles. Interestingly, IBV infection caused more pronounced reduction in
surface MHC-I expression compared to IAV. Importantly, the two viruses utilized two
distinct mechanisms for MHC-I downregulation. Our data demonstrated that while IAV
caused a global loss of MHC-I within influenza-infected cells, IBV infection resulted in the
preferential loss of MHC-I molecules from the cell surface, consequent of delayed MHC-I
trafficking to the cell surface, resulting from retaining MHC-I intracellularly during IBV
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infection. Overall, our study suggests that influenza viruses across both IAV and IBV
subtypes have the potential to downregulate MHC-I surface expression levels. Our
findings provide new insights into the host-pathogen interaction of influenza A and B
viruses and inform the design of novel vaccine strategies against influenza viruses.
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INTRODUCTION
Influenza A and B viruses (IAV and IBV, respectively) circulate
annually during seasonal epidemics causing significantmorbidity
and mortality. Two subtypes of IAV (H1N1 and H3N2) and
two antigenically distinct lineages of IBV (B-Victoria and
B-Yamagata) co-circulate in every season (1, 2). Protection
against influenza viruses can be mediated by strain-specific
or rare broadly cross-reactive antibodies, as well as broadly
cross-reactive CD8+ T cells (2, 3). Cytotoxic CD8+ T cells
provide protection by recognizing viral peptides loaded
onto MHC-I molecules on the cell surface of infected cells,
which triggers the delivery of cytotoxic molecules and
releasing antiviral cytokines to kill the infected cells (4, 5).
In this way, CD8+ T cells promote viral clearance and
recovery during seasonal as well as pandemic and avian
influenza virus infection, which share internally conserved
peptide sequences (6–10). As a result, and due to their
ability to cross-react across highly divergent influenza
strains, CD8+ T cells are considered an important target
for designing universal influenza vaccines that do not require
annual reformulation.
The key determinant of CD8+ T cell recognition of virally-
infected cells is the engagement of the T cell receptor (TCR) to
its cognate peptide/MHC-I complex. As MHC-I traffics through
the endoplasmic reticulum (ER), short peptides (7–13 amino
acids in length) derived from host or foreign proteins are
loaded onto MHC-I and then presented on the cell surface.
Thus, due to the crucial role of MHC-I in CD8+ T cell
recognition of the infected cells, many viruses such as HIV and
herpesviruses have evolved intricate mechanisms to interfere
with MHC-I presentation of viral peptides (11, 12). Such
escape mechanisms range from inhibiting the proteasome or
the delivery of peptides to the ER for loading onto MHC-
I to active retention of MHC-I in intracellular compartments
and/or increased rates of internalization and degradation of
MHC-I. While such virus-mediated downregulation of MHC-
I expression has been shown for a number of viruses (11, 12),
downregulation of MHC-I by influenza viruses has not been
reported thus far.
By examining the expression levels of MHC-I following IAV
or IBV infections, we show that both viruses reduce expression
of MHC-I in the late stages of infection in vitro, albeit via
two different mechanisms. While IAV causes degradation
of total MHC-I in the infected cells, IBV causes retention
of MHC-I in an intracellular compartment. Interestingly,
this seems to be a non-specific effect of the viral life cycle
as other surface host protein are downregulated equally,
and thus may not have specifically evolved to evade the
CD8+ T cell response. Overall, our study reveals that IAV
and IBV are capable of downregulating MHC-I expression.
Understanding the exact mechanisms underlying MHC-I
downregulation by influenza viruses and the impact on anti-
influenza T cell responses will inform the rational design of new
vaccine strategies.
MATERIALS AND METHODS
Cell Lines and Reagents
C1R cells or 721.221 cells (stable-transfectants expressing specific
HLA alleles) (University of Melbourne) and THP-1 cells (ATCC)
were propagated in RF10 media [RPMI-1640 with 10% heat-
inactivated FCS, 1mM MEM sodium pyruvate, 2mM L-
glutamine, 100mM MEM non-essential amino acids, 5mM
HEPES buffer solution, 55mM 2-ME, 100 U/ml penicillin,
and 100 mg/ml streptomycin; purchased from Gibco (Thermo
Fisher Scientific, Scoresby, VIC, Australia)]. Hygromycin B
(200µg/ml) or Geneticin (500µg/ml) were used as selection
markers (Invitrogen) of stable transfectants. A549 cells (ATCC)
were maintained in cDMEM [DMEM with 10% heat-inactivated
FCS, 2mM L-glutamine, 1mM Sodium pyruvate, 100 U/ml
penicillin and 100 mg/ml streptomycin; purchased from Gibco].
Viruses and Infections
Influenza A (A/Switzerland/9715293/2013, A/Hong Kong/4801
/2014, A/California/04/2009, A/PR8) and B (B/Malaysia/2506/04,
B/Brisbane/06/2008, B/Massachusetts/2/2012, B/Phuket/3073/
2013) viruses were grown in the allantoic cavity of day 10-
embryonated chicken eggs for 3 days at 35◦C and viral titres
were determined by plaque assay on MDCK cells. Influenza B
viruses were provided by Seqirus, Australia. For virus infections,
cells were washed once and resuspended in serum free media
before IAV or IBV viruses were added at an MOI of 5. Cells
were incubated with virus for 1 h at 37◦C, then cells were
washed with complete media (10% FCS) and cultured for the
appropriate time.
Antibody Staining and Flow Cytometry
Cells were stained with LIVE/DEADTM Fixable Near-IR or Aqua
(Molecular Probes, Eugene, OR, USA) and a panel of surface
markers in MACS buffer (PBS with 0.5% BSA and 2mM EDTA):
HLA-ABC Pe-Cy7 (1:200, w6/32, BD), HLA-ABCAF-700 (1:200,
w6/32, BioLegend), HLA-DR BV605 (1:100, L243, BioLegend),
CD71 Pe-Cy7 (1:100, RI7217, BioLegend), for 30min at 4◦C.
Cells were then washed, fixed and then permeabilized with
intracellular antibody staining using the BD Cytofix/Cytoperm
kit according to manufacturer’s instructions. For intracellular
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FIGURE 1 | Infection with IAV and IBV leads to downregulation of MHC-I. (A–C) Changes in surface MHC-I expression during in vitro IAV and IBV infection of A549
cells. Cells were infected with IAV/IBV or mock-treated and MHC-I (HLA-ABC) expression was analyzed on total live mock-treated samples and NP− or NP+ for
IAV/IBV-treated samples. (A) Representative FACS plots of NP staining and MHC-I expression. (B) Infections rates for different IAV and IBV strains. (C) HLA-ABC
expression on uninfected (NP−) and infected cells (NP+) as geometric Mean Fluorescence Intensities (MFI). (D) Relative HLA-ABC expression on uninfected (NP−)
and infected cells (NP+) compared to mock-treated cells. Mean and SEM are shown for n = 6, pooled data from two independent experiments, each performed in
triplicate. (E) Relative HLA-ABC expression on infected cells (NP+) compared to mock-treated cells, for a panel of IAV and IBV strains, across cell lines. Mean
(Continued)
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FIGURE 1 | value shown (n = 6, pooled data from two independent experiments, each performed in triplicate). (F) Relative HLA-ABC expression on infected cells
(NP+) compared to mock-treated cells, for IAV and IBV viruses, where each data point represents the mean value (as above) for one strain. (G) Timecourse of MHC-I
downregulation my IAV and IBV. Relative HLA-ABC expression on infected cells (NP+) compared to mock-treated cells, for IAV and IBV. The frequency of NP+ cells is
also shown. (H) Cell viability after influenza infection at different timepoints after infection. Mean and SEM are shown for n = 6, pooled data from two independent
experiments, each performed in triplicate. Statistical significance was determined using unpaired Student’s t-test throughout the figure with *p < 0.05, **p < 0.01,
***p < 0.001.
antibody staining the following antibodies were used: HLA-
ABCAF-700 (1:200, w6/32, BioLegend), ANP-FITC (1:200, 1331,
GeneTex), BNP-FITC (1:200, H89B, ThermoFisher). For the
detection of BHA protein on the surface of infected cells, cells
were firstly stained with a mouse monoclonal antibody specific
for B/Malaysia (MIA1.8E3.1E9) (13) for 30min at 4◦C and then
with a secondary goat anti-mouse PE (1:200, BD Pharmigen) for
30min at 4◦C, before fixation with the BD Cytofix/Cytoperm kit
according to manufacturer’s instructions. Samples were acquired
on LSR Fortessa (BD Biosciences). All flow cytometry data were
analyzed using FlowJo 10 (FlowJo, LLC).
Radiolabelling, Immunoprecipitation and
Endo-H Sensitivity Analysis
Cells were starved in methionine- and cysteine-free DMEM for
30min at 37◦C and then pulsed in the same media supplemented
with 35S-labeled methionine and cysteine (Express Protein
Labeling Mix, Perkin Elmer) at 200 µCi/ml for 15min at 37◦C.
Cells were then washed with ice-cold RF10 and then incubated
in RF10 at 37◦C. At the selected timepoints, cells were washed in
PBS and frozen. Cell pellets were lysed in 0.5% IGEPAL CA-630
(Sigma-Aldrich), 50mM Tris-HCl (pH 7.4), 5mM MgCl2with
Complete Protease Inhibitor Cocktail (Roche), and centrifuged
13,000× g for 10min to separate nuclei. Lysates were precleared
twice with normal mouse serum (Sigma-Aldrich) and protein G–
Sepharose and twice with protein G–Sepharose alone. MHC-I
was immunoprecipitated using w6/32 antibody and protein G–
Sepharose, and the immunoprecipitates were washed in NET
buffer (0.5% IGEPAL CA-630, 50mM Tris-Cl pH 7.4, 150mM
NaCl, 5mM EDTA) three times. Precipitates were treated with
Endoglycosidase Hf (New England Biolabs) according to the
manufacturer’s instructions. Proteins were denatured in reducing
LDS-PAGE sample buffer and separated on NuPAGE 4–12% Bis-
Tris precast gels (Life Technologies) before transferring onto
PVDF membranes using the iBlot system (Life Technologies).
Membranes were dried and exposed to a storage phosphor
screen (GE Healthcare) and imaged on a Typhoon imager
(GE Healthcare).
Statistical Analysis
An unpaired Student’s t-test was used to assess statistical
significance in Prism 7 (GraphPad) with ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001. Error bars indicate the mean± SEM.
RESULTS
IAV and IBV Downregulate MHC-I in Late
Stages of Viral Infection
To assess whether influenza virus infection affected MHC-I cell
surface expression, we infected human alveolar basal epithelial
A549 cells, frequently used as an in vitro model of influenza
virus infection, with a panel of IAV (A/PR8 H1N1, A/Cal09
pdm09H1N1, A/Switzerland A/H3N2, and A/Hong KongH3N2)
and IBV (B/Brisbane Vic, B/Malaysia Vic, B/Massachusetts
Yam, B/Phuket Yam) strains. After 16 h of infection, cells were
stained for surface MHC-I expression using a pan-MHC-I
antibody (w6/32) and intracellularly for IAV- or IBV-derived
nucleoprotein (NP) protein (Figure 1A). Using a multiplicity
of infection (MOI) of 5, the infection rates, as determined by
NP+ staining, differed between IAV and IBV (p < 0.001) viral
strains (Figure 1B). To account for any differences in infection
rates, we analyzed MHC-I expression on infected cells (NP+)
and uninfected cells (NP−) in influenza-treated cells, relative to
the MHC-I expression on mock-treated cells. For all IAV and
IBV strains, with the exception of A/PR8, NP+ cells expressed
significantly lower (p < 0.05) geometric mean fluorescence
intensity (gMFI) levels of surface MHC-I as compared to mock
treated cells (gMFIs: ∼2,400 for mock, ∼1,500 for IAV strains,
∼600–1,400 for IBV strains) (Figure 1C). In contrast, NP− cells
expressed variably higher MFI levels of MHC-I (gMFI: 3,500–
9,000) compared to the mock control (Figure 1C, left panel),
likely due to the effects of type I IFN secreted by influenza-
infected cells (14, 15). Overall, influenza virus infection resulted
in ∼40% downregulation of surface MHC-I for IAV and ∼45–
75% loss for IBV (Figure 1D).
To validate these results, we used the same panel of IAV
and IBV strains to infect a human class-I reduced (C1R)
lymphoblastoid cell line, engineered to stably express the highly
prevalent HLA-A2 allele (C1R-A2), as well as the human
monocyte-like THP-1 cell line. As above, we normalized for
differences between infection rates across cell lines and virus
strains, then measured MHC-I expression on infected NP+ cells
relative to mock-treated cells. Across all three cell lines tested,
both IAV and IBV infections resulted in the reduction of MHC-
I, although variably so across strains and cell lines (Figure 1E).
In A549 cells, the mean percentage of MHC-I expression of the
four different strains within IAV or IBV did not differ between
IAV and IBV, whereas in C1R-A2 cells, downregulation of MHC-
I was significantly greater for IBV (50% MHC-I remaining) than
for IAV (75%, p= 0.04) (Figure 1F). Additionally, in THP-1 cells,
IAV infection did not result in any downregulation of MHC-I
(meanMHC-I expression 108% compared tomock-treated cells),
while IBV infection resulted in∼56% loss of MHC-I (Figure 1F).
The lack of MHC-I downregulation by IAV in THP-1 cells could
not be attributed to lower infection rates, as their infection rates
were comparable to A549 cells (Figure S1A; Figure 1B).
We next assessed the kinetics of MHC-I downregulation
by IAV and IBV in C1R-A2 cells. For both IAVs and IBVs,
while infectivity increased over time,MHC-I downregulation was
observed at the very late stages of infection (16 h) (Figure 1G).
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Interestingly, for IBV at 8 h after infection, MHC-I was increased
compared to mock-treated cells. The viability of these cells was
not compromised following IAV or IBV infection (Figure 1H).
Overall, our data show that infection with IAV and IBV results in
dynamic changes of MHC-I expression.
Downregulation of HLA-A, -B, and -C
Alleles by IAV and IBV
Downregulation of MHC-I by HIV differs across MHC-I
allotypes, whereby, HLA-A allotypes are more susceptible than
HLA-B allotypes (16). Since A549 and THP-1 cell lines express
a diverse set of HLA-I alleles (A549: A∗25:01, A∗30:01, B∗18,
B∗44:03, C∗12:03, C∗16:01, and THP-1: A∗02, B∗15, C∗03)
(17, 18), we next assessed how different HLA-A, -B, and C
allotypes are downregulated during influenza infection. To that
end, we used a library of 14 C1R cell lines transduced with
single different HLA-A (A∗01:01, A∗02:01, A∗03:01, A∗24:02) or
HLA-B (B∗07:02, B∗08:01, B∗15:01, B∗18:01, B∗27:05, B∗35:01,
B∗44:02, B∗44:03, B∗44:05, B∗57:01) alleles. These cells were
infected with a representative IAV (A/Switzerland H3N2) or IBV
strain (B/Malaysia-Vic) (Figure S1B) andMHC-I expression was
assessed at 16 h after infection. For all allotypes, MHC-I was
significantly downregulated in NP+ cells following IAV infection
(16–58% reduction) and IBV infection (37–69% reduction), as
compared to their respective mock-treated cells (p < 0.05), with
the exception of HLA-B∗44:05 during IAV infection (Figure 2A).
In general, when all the HLA alleles were grouped together,
IBV infection resulted in significantly greater downregulation of
MHC-I (p = 0.002, n = 14 alleles) (Figure 2B). However, there
were no differences in MHC-I downregulation between HLA-A
and HLA-B alleles for either IAV or IBV (Figure 2C).
To assess downregulation of HLA-C alleles, we used a
library of human lymphoblastoid HLA-null 721.221 cell lines,
transduced with 10 different HLA-C alleles (C∗02:02, C∗03:04,
C∗04:01, C∗05:01, C∗06:02, C∗07:02, C∗12:02, C∗12:03, C∗16:01,
C∗18:01). 721.221 cells expressing A∗24:02 or B∗27:05 were
used for comparison between HLA-A, -B, and -C alleles in
the same cell type. All HLA-C alleles tested were significantly
(p < 0.0001) downregulated by either IAV or IBV, with only
∼20–40% of surface MHC-I remaining after 16 h of infection
(Figure 2D, Figure S1C). Interestingly, during IAV infection,
downregulation of all HLA-C alleles (70–80% reduction) was
significantly >A∗24:02 (36% reduction) or B∗27:05 (42%
reduction) (p < 0.0001). Overall, downregulation of MHC-I by
IAV and IBV viruses occurs across a range of HLA-A, B-, and
C- allotypes.
Differential Mechanisms Drive
Downregulation of MHC-I by IAV and IBV
Having observed substantial MHC-I downregulation across
virus strains, cell lines, and HLA allotypes, we dissected the
mechanisms driving MHC-I downregulation during IAV and
IBV infections. Firstly, to assess whether downregulation of
MHC-I was specific to surface MHC-I or whether it was
depleted intracellularly, C1R-A2 cells were infected with IAV
(A/Switzerland H3N2) or IBV (B/Malaysia-Vic) viruses before
surface and intracellular MHC-I expression were measured
using the same anti-MHC-I antibody (w6/32) conjugated to two
FIGURE 2 | Downregulation of HLA-A, -B, and -C alleles by IAV and IBV. (A)
Relative HLA-ABC expression on infected cells (NP+) compared to
mock-treated cells, for IAV and IBV, across C1R lines expressing different
HLA-A and -B alleles. Expression after infection for each allele is relative to that
allele’s respective mock-treated samples. Mean and SEM are shown for n = 6,
pooled data from two independent experiments, each performed in triplicate.
(B, C) Relative HLA-ABC expression on infected cells (NP+) compared to
mock-treated cells, for IAV and IBV, where each data point represents the
mean value (as above) for one allele. (D) Relative HLA-ABC expression on
infected cells (NP+) compared to mock-treated cells, for IAV and IBV, across
721.221 lines expressing different HLA-C alleles. A24:02 and
B*27:05-expressing lines were used for comparison. Expression after infection
for each allele is relative to that alleles respective mock-treated samples. Mean
and SEM are shown for n = 6, pooled data from two independent
experiments, each performed in triplicate. Statistical significance was
determined using unpaired Student’s t-test throughout the figure with **p <
0.01, ****p < 0.0001.
different fluorochromes (Pe-Cy7 for surface staining and AF-
700 for intracellular staining (Figure 3A). Interestingly, following
IAV infection, NP+ cells had significantly reduced levels (p <
0.001) of both surface (61% of mock) and intracellular MHC-I
(70% of mock) (Figure 3B). In contrast, following IBV infection,
intracellular MHC-I levels in NP+ cells were only marginally
affected (90% of mock, p = 0.01), while surface levels were
significantly reduced (p < 0.001, 39% of mock) (Figure 3B). This
discrepancy between IAV and IBV viruses suggested that the
two influenza types may employ different mechanisms toward
MHC-I downregulation.
We subsequently used drug inhibitors targeting different
pathways of endocytosis and recycling (Table 1), whereby C1R-
A2 cells were infected with IAV or IBV for 4 h before drug was
added for the remaining 12 h of infection (Figure 3C). Treatment
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FIGURE 3 | Differential mechanisms drive downregulation of MHC-I by IAV and IBV. (A, B) Downregulation of surface vs. intracellular HLA-ABC during IAV and IBV
infection. (A) Outline of experimental design. (B) Representative FACS plots and bar graphs for surface and intracellular HLA-ABC expression, for total live cells in
mock-treated samples and NP+ cells for IAV/IBV-treated samples. (C–E) Drug-mediated rescue of HLA-ABC downregulation. (C) Outline of experimental design. (D)
Relative HLA-ABC expression on infected cells (NP+) compared to mock-infected untreated cells, for IAV and IBV, treated with inhibitors of endocytosis and lysosomal
degradation. (E) Relative HLA-ABC expression on infected cells (NP+) compared to mock-infected untreated cells, for IAV and IBV, treated with inhibitors of the
proteasome. Mean and SEM are shown, throughout the figure, for n = 6, pooled data from two independent experiments, each performed in triplicate. Statistical
significance was determined using unpaired Student’s t-test throughout the figure with *p < 0.05, ***p < 0.001.
of uninfected cells with endocytosis inhibitors, only had a modest
effect on MHC-I expression (Figure S2A). In IAV-infected NP+
cells, there was a ∼44% reduction in MHC-I cell surface
expression in the untreated group, and this remained unchanged
when drugs were added to block endocytosis (Figure 3D). In
contrast, while untreated IBV-infected NP+ cells had a ∼70%
decrease in their surface MHC-I, treatment with Dynasore, an
inhibitor targeting dynamin-dependent endocytosis, resulted in
a significantly higher surface MHC-I expression (∼10% loss
of mock-treated cells, p = 0.003) (Figure 3D). Treatment with
Genistein, which inhibits clathrin-independent endocytosis, or
Chlorpromazine (CPZ, inhibits clathrin-dependent endocytosis)
also significantly reduced downregulation (p < 0.001), although
partially (∼55% reduction of MHC-I expression as compared
to ∼75% in mock-treated cells) (Figure 3D). Treatment with
NH4Cl, which blocks lysosomal degradation, did not have a
significant effect on MHC-I downregulation.
To further dissect the mechanism of MHC-I downregulation,
particularly following IAV infection, we treated IAV- or
IBV-infected cells with the proteasome inhibitor MG132, as
above, to determine whether preventing proteasome-mediated
degradation could prevent or restore MHC-I downregulation.
Indeed, treatment of either IAV- or IBV-infected cells with
MG132 significantly rescued MHC-I downregulation to ∼100%
(p < 0.001, Figure 3E).
In terms of the infection rates, it should be noted that a
treatment with the endocytosis inhibitors resulted in a modest
but significant reduction (p < 0.05) in the frequency of ANP+
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TABLE 1 | Summary of drug inhibitors, their target pathway and their effect on MHC-I downregulation.
Inhibitor Concentration Pathway targeted MHC-I recovery during IAV infection MHC-I recovery during IBV infection
Dynasore 50µM Dynamin-dependent endocytosis − +++
Genistein 25µg/ml Clathrin-independent endocytosis – +
Chlorpromazine (CPZ) 10µg/ml Clathrin-dependent endocytosis – +
NH4Cl 10µM Lysosome-mediated degradation – –
MG132 5µM Proteosome-mediated degradation +++ ++
and BNP+ cells Figure S2B), although this did not affect the
gMFI expression levels of ANP and BNP proteins within NP+
cells (p > 0.05), with the exception of a modest decrease
in BNP expression following treatment with Chlorpromazine
(Figure S2C). Similarly, the viability of cells treated with the
endocytosis inhibitors following influenza virus infection was not
significantly different from that of infected and untreated cells,
again with the exception of Chlorpromazine (Figure S2D). In
case of MG132, however, both IAV and IBV infection rates (37
and 35%, respectively, with MG132) were significantly reduced
(p < 0.01) compared to untreated cells (55 and 70%, respectively,
in the untreated groups) (Figure S2E), and the BNP gMFI
expression levels was significantly (p < 0.001) reduced from
5,312 untreated to 2,243 withMG132 (Figure S2F). Additionally,
cell viability was substantially lower following MG132 treatment
(∼30% compared to 80–90% for untreated cells) (Figure S2G),
which is likely due to the ability ofMG132 to induce cell apoptosis
(19). Thus, while our flow cytometric analysis is focused on live
cells that express influenza NP proteins, the effects of MG132
on rescuing IBV-mediated downregulation of MHC-I, may be a
non-specific result of reduced infection/viral protein expression.
Overall, our data suggest a mechanism of MHC-I
downregulation whereby IAV causes loss of total MHC-I
from the cell surface and intracellularly that is independent of
endocytosis but dependent on proteasomal degradation, while
IBV causes a loss of surface MHC-I, but not intracellular MHC-I,
which can be prevented or reversed by blocking endocytosis of
surface MHC-I.
Delayed Trafficking of MHC-I to the Cell
Surface During IBV Infection
Having shown that IAV infection results in a global loss of
MHC-I, likely in a proteasome mediated manner, we focused on
dissecting the mechanism underlying the loss of surface MHC-
I by IBV. Given that IBV causes MHC-I downregulation on the
cell surface, but not intracellularly, and that this can be rescued by
inhibiting endocytosis, we investigated whether the loss of MHC-
I from the cell surface following IBV infection was due to: (1)
delayed MHC-I trafficking to the cell surface; or (2) whether IBV
infection increased MHC-I internalization and degradation rate.
To assess the rate at which MHC-I traffics to the cell surface,
we exposed mock or IBV-infected C1R-A2 cells to an acid buffer
(pH 2.0), which results in the loss of the MHC-I complex from
the cell surface (“acid-stripping”) (20). We then measured the
increase of surface MHC-I expression at 20min intervals for
up to 100min (Figure 4A). Surface MHC-I expression of mock-
infected cells was significantly higher (p < 0.001) compared to
IBV-infected cells at 60min after acid-stripping and continued
to be significantly higher up to 100min (Figures 4B,C). Overall,
MHC-I expression on mock-infected cells gradually increased
up to 12-fold at 100min after acid-stripping, when compared
to 0min. In contrast, IBV-infected cells (NP+) only increased
by 2-fold after 100min (Figure 4D). Consistently, the frequency
of cells expressing MHC-I increased from 1 to 80% for mock-
infected cells, but only from 12 to 57% for IBV-infected cells, with
significant differences (p< 0.001) in themock-infected cells from
60min onwards after stripping (Figure 4E). These data indicate
that during IBV infection, the rate at which MHC-I traffics to the
cell surface is significantly reduced.
To determine whether the rate of surface MHC-I
internalization and subsequent degradation are also affected,
we fluorescently labeled surface MHC-I of mock- or IBV-
infected cells (16 h) and, after washing off any excess antibody,
determined the rate at which the MHC-I signal was reduced,
reflecting internalization and degradation of MHC-I (Figure 4F).
Both mock and IBV-infected cells exhibited a slight gradual loss
of MHC-I although this was less evident for IBV due to already
significantly reduced MHC-I levels at 16 h after infection
(Figure 4G). Relative to their respective t = 0, both mock and
IBV-infected cells had a small reduction (∼20%) in MHC-I
expression by 100min after staining (Figure 4H), suggesting that
IBV does not increase the rate at which MHC-I is internalized
and degraded. While this may seem contrary to the ability
of the endocytosis inhibitor Dynasore to rescue or prevent
IBV-mediated MHC-I downregulation, it should be noted that
Dynasore may be retaining existing MHC-I on the cell surface
thus stabilizing its levels, regardless of whether new MHC-I is
delivered to the surface or not.
Thus, during IBV infection, MHC-I trafficking to the cell
surface is delayed, suggesting that MHC-I is retained in an
intracellular compartment during IBV infection.
MHC-I Is not Retained in the ER During
IBV Infection
Retention of MHC-I within the ER is a common immune
evasion strategy employed by many viruses, such as human
cytomegalovirus (21) and adenovirus (22). To determine
whether IBV retains MHC-I in the ER, we performed an
Endo-H sensitivity analysis on IBV-infected (16 h) or mock-
treated C1R-A2 cells to measure MHC-I in the ER (Endo-H
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FIGURE 4 | Delayed trafficking of MHC-I to the cell surface during IBV infection. (A– E) Rates of MHC-I trafficking to the cell surface during IBV infection. (A) Outline of
experimental design. (B) Representative FACS plots for mock and IBV-treated cells. (C) MHC-I expression at different timepoints after stripping, expressed as MFIs.
(D) Fold change in MHC-I expression at different timepoints after stripping, relative to 0min after stripping. (E) Frequency of MHC-I+ cells at different timepoints after
stripping. (F–H) Rates of MHC-I internalization and degradation from the cell surface during IBV infection. (F) Outline of experimental design. (G) MHC-I expression at
different timepoints after staining, expressed as MFIs. (H) Relative MHC-I expression at different timepoints after staining, relative to 0min. (C,G) Mean and SEM are
shown, n = 3, from one experiment, due to variations in flow cytometer settings between experiments, with similar trends observed between two independent
experiments. (D,E,H) Mean and SEM are shown, for n = 6, pooled data from two independent experiments, each performed in triplicate. Statistical significance was
determined using unpaired Student’s t-test throughout the figure with **p < 0.01, ***p < 0.001.
sensitive) or in the Golgi and post-Golgi compartments (Endo-
H resistant) over 90min following MHC-I radiolabelling and
immunoprecipitation (Figure 5A). For both mock-treated and
IBV-infection, at time 0 after radio-labeling the majority of
radiolabelled MHC-I were Endo-H sensitive, indicative of ER
localization (Figures 5B–D), whereas only 20–30% of newly
synthesized MHC-I were Endo-H resistant, indicative of passage
through the Golgi. However, this gradually increased to 70–80%
by 90min (Figures 5B–D). Therefore, the kinetics of Endo-H
resistance were comparable between IBV-infected and mock-
treated cells (Figures 5B–D), suggesting that MHC-I is not
retained in the ER and traffics with normal kinetics through the
Golgi apparatus during IBV infection.
Selective Downregulation of Surface Host
but not Viral Surface Proteins During
IBV Infection
To determine whether downregulation is specific to MHC-I
or whether it is also applicable to other surface proteins, we
assessed expression of MHC-II (HLA-DR) and the transferrin
receptor (TfR or CD71) on IBV-infected and mock-treated
cells. All three surface proteins (MHC-I, HLA-DR, and CD71),
showed significant downregulation (p < 0.0001) on IBV NP+
cells, with each protein having a ∼70% reduction in expression
levels (Figure 6A).
The downregulation of surface proteins by IBV in the late
stages of infection is intriguing, as altered protein trafficking
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FIGURE 5 | MHC-I is not retained in the ER during IBV infection. (A) Outline of experimental design. (B) Autoradiograms of Endo-H sensitivity of immunoprecipitated
(IP) MHC-I (w6/32) from C1R-A2 cells, which were either infected with IBV for 16 h or mock-treated, and then metabolically radiolabelled with [35S]methionine and
[35S]cysteine and chased for the indicated timepoints. NMS: immunoprecipitated obtained with normal mouse serum as a control. R: Endo-H resistant MHC-I. S:
Endo-H sensitive MHC-I. (C) Percent of Endo-H sensitive MHC-I in mock or IBV-treated cells, based on “R” band intensity at each timepoint compare to Endo-H
untreated band intensity (columns 2 or 7). (D) Fractions of Endo-H sensitive/resistant MHC-I in mock or IBV-infected cells, based on S/R band intensity relative to their
sum for each timepoint. (B–D) Data are representative of two independent experiments.
to the cell surface would need to be selective to host, but
not viral proteins, so as not to interfere with virion assembly.
To determine whether this might be the case, we measured
the surface expression levels of host proteins (MHC-I) and
the viral IBV haemagglutinin (BHA) protein at 12 and 16 h
after infection. Consistent with our previous data, IBV infection
resulted in significant downregulation of MHC-I protein at
16 h after infection compared to mock-treated cells (p = 0.02)
(Figure 6B). Importantly, the surface expression of MHC-I was
significantly reduced between 12 and 16 h (p = 0.006). However,
the surface expression of the BHA protein was stable between
12 and 16 h [MFI of 257 and 273, respectively (p = 0.82)]
(Figure 6B), suggesting that the block on trafficking imposed
by IBV does not affect the trafficking of viral proteins to the
cell surface.
Overall, our data show that infection with IAVs and IBVs
leads to downregulation of MHC-I in the late stages of infection
via two distinct mechanisms. While IAV causes a global
loss of MHC-I within influenza-infected cells, IBV infection
results in the preferential loss of MHC-I molecules from the
cell surface, due to delayed MHC-I trafficking to the cell
surface, resulting from retaining MHC-I intracellularly during
IBV infection.
DISCUSSION
Given that IAV and IBV circulate annually and current influenza
virus vaccines only provide modest efficacy (2), a better
understanding of the immune response to IAV and IBV and the
underlying host-pathogen interactions are necessary to improve
vaccine design. Due to the ability of CD8+ T cells to confer
broad and universal cross-protection, a deeper understanding
of T cell responses to IAV and, even more so the understudied
but clinically relevant IBV, is needed. Here, we show that
both influenza A and B viruses downregulate MHC-I in the
late stages of their infection cycles in vitro, albeit via two
different mechanisms. This observation could have significant
immunological consequences.
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FIGURE 6 | Selective loss of host but not viral surface proteins during IBV infection. (A) Expression levels of host (MHC-I, HLA-DR, CD71) proteins and the IBV HA
protein on C1R-A2 cells infected with IBV for 16 h or mock-treated. (B) No downregulation of the BHA protein between 12 and 16 h. Representative FACS plots are
shown. Mean and SEM are shown, throughout the figure, for n = 6, pooled data from two independent experiments, each performed in triplicate. Statistical
significance was determined using unpaired Student’s t-test throughout the figure with *p < 0.05, **p < 0.01, ***p < 0.001.
MHC-I downregulation observed after influenza virus
infection is specific for IAV- or IBV-infected cells, as determined
by NP intracellular expression, while uninfected “bystander”
cells exhibited an increase in MHC-I expression, although
variably across influenza strains. This could reflect the activity
of IFN released by infected cells as IFN can cause upregulation
of MHC-I (14). While this downregulation was only modest for
IAV (30–40% reduction of MHC-I), it was substantially more
pronounced for IBV (60–70% reduction), and this was consistent
across multiple IAV/IBV strains, cell lines, and HLA alleles. The
kinetics of MHC-I downregulation are intriguing as this only
occurs in the late stages of infection (16 h), when the influenza
virions assemble and bud off. It would also be important to verify
our observation of MHC-I downregulation by IAV and IBV in
primary cells as well as in vivomodels of influenza infection.
Our data are suggestive of two different mechanisms of
downregulation by IAV and IBV. We hypothesize that IAV leads
to either reduced transcription of MHC-I, specifically or as a
result of general host translation shut-off, or degradation of
intracellular pools of MHC-I, which is supported by the effects of
proteasomal inhibitor MG132 on IAV-mediated downregulation
and the loss of intracellular MHC-I. Interestingly, it has been
previously reported that in the late stages of infection by
IAV (16 h) the mRNA levels of MHC-I, among other antiviral
transcripts, are greatly reduced (14). This is consistent with the
ability of IAV to induce host protein shut-off in multiple ways
(23). We hypothesize that this effect may be driving the reduced
expression of MHC-I.
In contrast, we postulate that during IBV infection MHC-I is
retained in an undefined intracellular location. Our hypothesis
that IBV retains MHC-I, and likely other host proteins, in an
intracellular compartment is supported by the delayed trafficking
of MHC-I to the cell surface, the ability of endocytosis inhibitors
to restore or prevent this process, contrary to that of IAV.
Investigations into IBV-mediated MHC-I downregulation using
radiolabelling and an Endo-H sensitivity assay showed that
the kinetics MHC-I traffic through the Golgi were comparable
betweenmock-treated and IBV-infected cells, supporting the idea
that the retention in MHC-I occurs after trafficking though the
Golgi apparatus, where protein glycosylation renders molecules
Endo-H resistant. Considering MHC-I had reduced arrival at the
cell surface in IBV infected cells, this suggests that the MHC-I
molecules are retained en route to the plasma membrane and
potentially sequestered in an undefined vesicular location. The
exact location of the MHC-I-containing vesicle remains elusive,
and further studies are underway to assess that. In addition,
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identifying the viral factors driving this downregulation ofMHC-
I in the late stages of IAV and IBVwould be of utmost importance
in dissecting the mechanisms and immunological consequences
ofMHC-I downregulation, as well as the differences between IAV
and IBV.
Downregulation of MHC-I often leads to reduced CD8+ T
cell responses (12). While we have yet to determine the biological
consequences of the observed downregulation, we speculate that
there might be differences between IAV and IBV, strains and
cell types. Particularly, since ∼60–70% of MHC-I remains on
the cell surface of IAV-infected cells, the effects on the CD8+
T cell response may only be modest, especially for CD8+ T
cells of high functional avidity. It is also pertinent to note
that since downregulation is only observed in the late stages
of infection, CD8+ T cells would still be able to recognize
infected cells prior to that. In fact, at 8 h after IBV infection,
MHC-I is higher compared to mock-treated cells, which may
increase the susceptibility of these infected cells to CD8+ T cell-
mediated killing. Additionally, downregulation of MHC-I would
likely make infected cells more susceptible to NK cell-mediated
cytotoxicity, especially in the late stages of infection, when viral
proteins are abundant on the cell surface which can be targeted
by antibodies to initiate antibody-dependent cellular cytotoxicity.
The effect of IBV appears not to be specific for MHC-I, as
CD71 (TfR) and HLA-DR (MHC-II) were also downregulated
from the surface of infected cells. Combined with the timing of
this, it is conceivable that the virus manipulates host intracellular
trafficking to promote the delivery of viral proteins to the cell
surface for virion assembly and egress. Indeed, the cell surface
expression levels of the BHA protein were stable between 12 and
16 h. Thus, this process may have not specifically evolved to evade
CD8+ T cells but MHC-I downregulation may be a side-effect of
the IBV life cycle.
Overall, our study suggests that in the late stages of infection,
MHC-I levels are significantly reduced on both IAV- and IBV-
infected cells via two different processes, likely as a by-product
of the viral life cycle. This downregulation could have significant
effects on the immune response against IAV and IBV and also
highlights biological differences between IAV and IBV.
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Figure S1 | Infection rates of THP-1 cells and C1R or 221 cells expressing
different HLA allotypes. (A) Infections rates for THP-1 cells infected with different
IAV or IBV strains. (B) Infections rates for different HLA expressing C1R cells
infected with IAV or IBV. (C) Infections rates for different HLA expressing 221 cells
infected with IAV or IBV. Mean and SEM are shown, throughout the figure, for
n = 6, pooled data from two independent experiments, each performed in
triplicate.
Figure S2 | Effect of drug inhibitors on infection rates, NP expression levels and
cell viability. (A) Effect of drug treatment on MHC-I expression in uninfected cells.
(B,C) Infections rates (%NP+) (A) and NP expression within NP+ cells (B) for cells
infected with IAV or IBV and treated with endocytosis inhibitors. (D) Cell viability for
cells infected with IAV or IBV and treated with endocytosis inhibitors. Mock cells
were not infected and untreated. (E,F) Infections rates (%NP+) (E) and NP
expression within NP+ cells (F) for cells infected with IAV or IBV and treated with
MG132. (G) Cell viability for cells infected with IAV or IBV and treated with
endocytosis inhibitors. Mock cells were not infected and untreated. Mean and
SEM are shown, throughout the figure, for n = 6, pooled data from two
independent experiments, each performed in triplicate. Statistical significance was
determined using unpaired Student’s t-test throughout the figure with ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001.
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